多西他赛联合奥沙利铂5―氟尿嘧啶治疗晚期胃癌临床研究.docVIP

多西他赛联合奥沙利铂5―氟尿嘧啶治疗晚期胃癌临床研究 　　[摘要] 目的 观察多西他赛联合奥沙利铂、5-氟尿嘧啶对晚期胃癌患者的治疗效果。 方法 回顾性分析62例接受多西他赛联合奥沙利铂、5-氟尿嘧啶治疗方案的晚期胃癌患者临床资料，观察近期疗效、毒副反应、中位无进展生存（PFS）时间及总生存（OS）时间。 结果 62例患者中，部分缓解17例，病情稳定32例，疾病进展13例，总有效率为27.42%，疾病控制率为79.03%。中位随访14.2个月，中位PFS为5.7个月（95%CI 3.31～7.90），中位OS为13.7个月（95%CI 2.2～22.6）。常见的不良反应为骨髓抑制和恶心、呕吐等消化道症状。多因素COX分析提示，近期疗效是PFS与OS的独立预后因素，治疗前患者的CA19-9水平是PFS的独立预后因素（P 0.05）。 结论 晚期胃癌接受多西他赛联合奥沙利铂、5-氟尿嘧啶的治疗方案，可耐受毒副反应，可作为晚期胃癌的化疗方案。 　　[关键词] 晚期胃癌；多西他赛；奥沙利铂；5-氟尿嘧啶 　　[中图分类号] R969.4 [文献标识码] A [文章编号] 1673-7210（2016）09（b）-0096-04 　　[Abstract] Objective To evaluate the clinical efficacy of Docetaxel， Oxaliplatin and 5-Fluorouracil combination chemotherapy in the treatment of patients with advanced gastric cancer. Methods The clinical data including short-term effects ， toxic and side effect ， the median progression-free survival （PFS） time and overall survival （OS） time of sixty-two advanced gastric cancer patients who were given the combination therapy regimen of Docetaxel， Oxaliplatin and 5-Fluorouracil were analyzed retrospectively. Results Among 62 cases of patients， 17 cases had partial remission， 32 cases had stable disease， 13 cases had progression of disease the overall response rate was 27.42%， disease control rate was 79.03%. The median follow-up of 14.2 months， PFS was 5.7 months （95%CI 3.31-7.90）， and OS was 13.7 months （95%CI 2.2-22.6）. The most common adverse effects were bone marrow suppression， gastro-intestinal toxicity. Multi-factor COX regression analysis showed that short-term effects was the independent prognostic factor of PFS and OS， and the CA19-9 level before treatment was the independent prognostic factors of PFS （P 0.05）. Conclusion The advanced gastric cancer patients who received the combination chemotherapy regimen of Docetaxel， Oxaliplatin and 5-Fluorouracil showed effectively and safely， and the combination chemotherapy regimen is worthy of clinical promotion for patients with advanced gastric cancer. 　　[Key words] Advanced gastric cancer； Docet